Astria Therapeutics to Present Final ALPHA-STAR Trial Results for Navenibart in Hereditary Angioedema

Reuters

2025/10/31

Astria <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to Present Final ALPHA-STAR Trial Results for Navenibart in Hereditary Angioedema

Astria Therapeutics Inc. announced that it will present final results from the ALPHA-STAR Phase 1b/2 clinical trial of navenibart in individuals with hereditary angioedema $(HAE)$ at the upcoming American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting. The meeting is scheduled to take place from November 6-10, 2025, in Orlando, Florida. The results will be presented by Dr. Aleena Banerji of Harvard Medical School on November 8, 2025, during a poster session in the West Exhibit Hall. The data to be presented will provide additional information from the clinical trial evaluating navenibart for HAE.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251031805612) on October 31, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2579693684"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579693684\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579693684?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579693684","market":"us","top_or_hot":-1,"title":"Astria Therapeutics to Present Final ALPHA-STAR Trial Results for Navenibart in Hereditary Angioedema","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Astria <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Present Final ALPHA-STAR Trial Results for Navenibart in Hereditary Angioedema\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ATXS\">Astria Therapeutics Inc</a>. announced that it will present final results from the ALPHA-STAR Phase 1b/2 clinical trial of navenibart in individuals with hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a> at the upcoming American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting. The meeting is scheduled to take place from November 6-10, 2025, in Orlando, Florida. The results will be presented by Dr. Aleena Banerji of Harvard Medical School on November 8, 2025, during a poster session in the West Exhibit Hall. The data to be presented will provide additional information from the clinical trial evaluating navenibart for HAE.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251031805612) on October 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Astria Therapeutics to Present Final ALPHA-STAR Trial Results for Navenibart in Hereditary Angioedema</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstria Therapeutics to Present Final ALPHA-STAR Trial Results for Navenibart in Hereditary Angioedema\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-31 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Astria <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Present Final ALPHA-STAR Trial Results for Navenibart in Hereditary Angioedema\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ATXS\">Astria Therapeutics Inc</a>. announced that it will present final results from the ALPHA-STAR Phase 1b/2 clinical trial of navenibart in individuals with hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a> at the upcoming American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting. The meeting is scheduled to take place from November 6-10, 2025, in Orlando, Florida. The results will be presented by Dr. Aleena Banerji of Harvard Medical School on November 8, 2025, during a poster session in the West Exhibit Hall. The data to be presented will provide additional information from the clinical trial evaluating navenibart for HAE.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251031805612) on October 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL7PKPwF:1","article_id":"2579693684","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579693684","pubTimestamp":1761912036,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Astria Therapeutics Inc. announced that it will present final results from the ALPHA-STAR Phase 1b/2 clinical trial of navenibart in individuals with hereditary angioedema  at the upcoming American College of Allergy, Asthma, and Immunology  Annual Scientific Meeting. The meeting is scheduled to take place from November 6-10, 2025, in Orlando, Florida. The results will be presented by Dr. Aleena Banerji of Harvard Medical School on November 8, 2025, during a poster session in the West Exhibit Hall. The data to be presented will provide additional information from the clinical trial evaluating navenibart for HAE.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ATXS":"Astria Therapeutics Inc"},"translate_title":"Astria Therapeutics将公布Navenibart治疗遗传性血管性水肿的最终ALPHA-STAR试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATXS":0.9},"content_text":"Astria Therapeutics to Present Final ALPHA-STAR Trial Results for Navenibart in Hereditary Angioedema\n    \n\nAstria Therapeutics Inc. announced that it will present final results from the ALPHA-STAR Phase 1b/2 clinical trial of navenibart in individuals with hereditary angioedema $(HAE)$ at the upcoming American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting. The meeting is scheduled to take place from November 6-10, 2025, in Orlando, Florida. The results will be presented by Dr. Aleena Banerji of Harvard Medical School on November 8, 2025, during a poster session in the West Exhibit Hall. The data to be presented will provide additional information from the clinical trial evaluating navenibart for HAE.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251031805612) on October 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}